SecBot SecBot
PRESS-RELEASE ·Filed Jun 2, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is a routine early-stage clinical update with no data readout until H2 2027. No immediate catalyst for the stock. Monitor for DSMB safety reviews and any interim updates, but the next material event is topline data release.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$46.93
T+0 close · Jun 2, 2026 · via day close
Latest settled
+30.31%
T+60 · $61.16
Vs SPY
+27.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $46.93entry
  2. T+1 · 6mo ago +3.90%α +3.49% · $48.76
  3. T+5 · 5mo ago −3.22%α +0.60% · $45.42
  4. T+20 · 5mo ago +24.42%α +25.42% · $58.39
  5. T+60 · 3mo ago +30.31%α +27.81% · $61.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vaxcyte dosed the first participant in a Phase 1 first-in-human study of VAX-A1, a prophylactic vaccine candidate for Group A Streptococcus. This is an early-stage clinical milestone with no efficacy data yet; topline results are not expected until H2 2027.

Key Facts

  • First participant dosed in Phase 1 study of VAX-A1 for Group A Strep.
  • Study is randomized, double-blind, placebo-controlled, dose-escalation, two-stage, enrolling ~80 healthy adults aged 18-40.
  • Primary objective: safety and tolerability; secondary: antigen-specific immune responses.
  • Topline data expected in second half of 2027.
  • Group A Strep causes ~800M new cases and >600,000 deaths annually worldwide; no approved vaccine exists.
  • VAX-A1 targets four conserved antigens (ScpA, SLO, SpyAD, modified GACPR) using Vaxcyte's cell-free protein synthesis platform.

Financial Impact

No financial data disclosed; early-stage clinical milestone with no revenue impact.

Risk Factors

  • Clinical failure or safety issues in Phase 1 could halt the program.
  • Long timeline to data (H2 2027) means no near-term catalyst.
  • Group A Strep vaccine development has historically been challenging with prior failures.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3305592

US Market Status

Market Closed · Opens Wed (13h 14m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026